My response, published today on STAT, to Feuerstei
Post# of 154899
(Total Views: 2174)
Posted On: 07/08/2020 11:49:05 AM
My response, published today on STAT, to Feuerstein's story on leronlimab:
This one-sided and completely slanted story leaves out important details such as the 60-plus patients treated with leronlimab on an emergency basis at prestigious hospitals, such as Montefiore, Novant, and UCLA, where the well-respected treating physicians, who administered leronlimab to their COVID-19 patients, attributed successful outcomes to this drug.
This story also leaves out the bloodwork analysis of leronlimab-treated COVID-19 patients by respected virologist Dr. Bruce Patterson, who claims leronlimab is the only drug that quells the cytokine storm, reduces the COVID-19 viral load, and helps restore the immune system in COVID-19 patients.
With respect to Nader Pourhassan's neutral comment that he cannot predict the outcome of ongoing COVID-19 clinical trials for leronlimab, no other credible answer was possible given that the trials are double-blinded, which is what Pourhassan correctly noted in his answer to this question.
Finally, it would be helpful to know whether you are short Cytodyn, which, if is the case, suggests a bias that should be disclosed.
LM
This one-sided and completely slanted story leaves out important details such as the 60-plus patients treated with leronlimab on an emergency basis at prestigious hospitals, such as Montefiore, Novant, and UCLA, where the well-respected treating physicians, who administered leronlimab to their COVID-19 patients, attributed successful outcomes to this drug.
This story also leaves out the bloodwork analysis of leronlimab-treated COVID-19 patients by respected virologist Dr. Bruce Patterson, who claims leronlimab is the only drug that quells the cytokine storm, reduces the COVID-19 viral load, and helps restore the immune system in COVID-19 patients.
With respect to Nader Pourhassan's neutral comment that he cannot predict the outcome of ongoing COVID-19 clinical trials for leronlimab, no other credible answer was possible given that the trials are double-blinded, which is what Pourhassan correctly noted in his answer to this question.
Finally, it would be helpful to know whether you are short Cytodyn, which, if is the case, suggests a bias that should be disclosed.
LM
(19)
(0)CytoDyn Inc (CYDY) Stock Research Links
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]